Stereotaxis Future Growth

Future criteria checks 2/6

Stereotaxis is forecast to grow earnings and revenue by 29.3% and 43% per annum respectively while EPS is expected to grow by 20.6% per annum.

Key information

29.3%

Earnings growth rate

20.6%

EPS growth rate

Medical Equipment earnings growth	17.3%
Revenue growth rate	43.0%
Future return on equity	n/a
Analyst coverage	Low
Last updated	22 Aug 2024

Recent future growth updates

Recent updates

US$9.33 - That's What Analysts Think Stereotaxis, Inc. (NYSEMKT:STXS) Is Worth After These Results

Feb 28

Is Stereotaxis (NYSEMKT:STXS) A Risky Investment?

Jan 28

Investors Who Bought Stereotaxis (NYSEMKT:STXS) Shares Five Years Ago Are Now Up 597%

Dec 24

What Kind Of Investors Own Most Of Stereotaxis, Inc. (NYSEMKT:STXS)?

Nov 19

Earnings and Revenue Growth Forecasts

NYSEAM:STXS - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	67	-9	N/A	N/A	3
12/31/2025	41	-16	N/A	N/A	4
12/31/2024	27	-20	N/A	N/A	4
6/30/2024	24	-22	-9	-9	N/A
3/31/2024	27	-21	-9	-9	N/A
12/31/2023	27	-22	-10	-9	N/A
9/30/2023	30	-21	-10	-9	N/A
6/30/2023	29	-21	-12	-11	N/A
3/31/2023	28	-21	-11	-9	N/A
12/31/2022	28	-20	-11	-8	N/A
9/30/2022	29	-19	-10	-7	N/A
6/30/2022	31	-19	-9	-6	N/A
3/31/2022	33	-15	-7	-5	N/A
12/31/2021	35	-12	-4	-3	N/A
9/30/2021	34	-10	-2	-1	N/A
6/30/2021	33	-7	-1	0	N/A
3/31/2021	29	-8	-2	-2	N/A
12/31/2020	27	-8	-4	-4	N/A
9/30/2020	27	-8	-6	-6	N/A
6/30/2020	26	-6	-6	-6	N/A
3/31/2020	28	-6	-5	-5	N/A
12/31/2019	29	-6	-5	-5	N/A
9/30/2019	29	-6	-4	-3	N/A
6/30/2019	29	-6	-4	-3	N/A
3/31/2019	29	-4	-3	-2	N/A
12/31/2018	29	-1	-3	-3	N/A
9/30/2018	30	-3	-3	-3	N/A
6/30/2018	30	-7	-3	-3	N/A
3/31/2018	31	-7	N/A	-4	N/A
12/31/2017	31	-7	N/A	-5	N/A
9/30/2017	31	1	N/A	-4	N/A
6/30/2017	31	-7	N/A	-5	N/A
3/31/2017	30	-9	N/A	-5	N/A
12/31/2016	32	-12	N/A	-7	N/A
9/30/2016	34	-19	N/A	-5	N/A
6/30/2016	35	-7	N/A	-3	N/A
3/31/2016	37	-6	N/A	-3	N/A
12/31/2015	38	-7	N/A	-3	N/A
9/30/2015	38	-5	N/A	-6	N/A
6/30/2015	38	-4	N/A	-8	N/A
3/31/2015	36	-4	N/A	-10	N/A
12/31/2014	35	-5	N/A	-9	N/A
9/30/2014	34	-10	N/A	-9	N/A
6/30/2014	36	-67	N/A	-8	N/A
3/31/2014	38	-68	N/A	-8	N/A
12/31/2013	38	-69	N/A	-6	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: STXS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: STXS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: STXS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: STXS's revenue (43% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: STXS's revenue (43% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if STXS's Return on Equity is forecast to be high in 3 years time

Stereotaxis Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Stereotaxis, Inc. Provides Revenue Guidance for the Full Year 2024

Consensus EPS estimates fall by 20%

Consensus revenue estimates decrease by 10%, EPS upgraded

Price target decreased by 7.8% to US$4.70

No longer forecast to breakeven

Stereotaxis, Inc. Reiterates Revenue Guidance for the Year 2023

Recent updates

Stereotaxis, Inc. to Report Q3, 2024 Results on Nov 11, 2024

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Stereotaxis, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Stereotaxis Announces the Appointment of Nachum 'Homi' Shamir to Its Board of Directors

Stereotaxis, Inc. Announces the Successful Treatment of the First Heart Rhythm Patients by Penn Presbyterian Medical Center Utilizing the Advanced Genesis Robotic Magnetic Navigation System

Stereotaxis, Inc. Provides Revenue Guidance for the Full Year 2024

Stereotaxis, Inc. (NYSEAM:STXS) entered into a definitive share purchase agreement to acquire APT EP Inc.

Stereotaxis, Inc. to Report Q1, 2024 Results on May 13, 2024

New minor risk - Shareholder dilution

Stereotaxis, Inc., Annual General Meeting, May 15, 2024

Consensus EPS estimates fall by 20%

Consensus revenue estimates decrease by 10%, EPS upgraded

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Stereotaxis, Inc. Announces Regulatory Submissions of the MAGiC Ablation Catheter in Europe and the United States

Stereotaxis, Inc. to Report Q4, 2023 Results on Mar 04, 2024

New minor risk - Share price stability

Stereotaxis Announces First Patients Successfully Treated Using Magic Ablation Catheter

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 7.8% to US$4.70

Stereotaxis, Inc. to Report Q3, 2023 Results on Nov 09, 2023

No longer forecast to breakeven

Stereotaxis, Inc. Reiterates Revenue Guidance for the Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Stereotaxis, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Stereotaxis to Initiate First-In-Human Trial to Support CE Mark Application of Magic Catheter

Price target decreased by 7.5% to US$4.90

Stereotaxis, Inc. Announces the First Treatment of Patients with Newly Launched Genesis Robotic Magnetic Navigation System At Advocate Christ Medical Center in Chicago, Illinois

Consensus EPS estimates fall by 21%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Forecast to breakeven in 2025

Price target decreased by 7.1% to US$5.42

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

Stereotaxis, Inc. to Report Q4, 2022 Results on Mar 03, 2023

Stereotaxis Announces the Successful Treatment of Patients Using the Latest Genesis Robotic Magnetic Navigation

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$6.63

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Stereotaxis, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Overland Park Regional Medical Center Extends Leadership in Robotic Treatment of Heart Rhythm Disorders with Plans for Second Stereotaxis System

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Stereotaxis, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Stereotaxis, Inc.(NYSEAM:STXS) dropped from Russell 2000 Dynamic Index

Price target decreased to US$9.42

Stereotaxis, Inc. Reiterates Revenue Guidance for the Full Year 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$10.25

Insufficient new directors

Stereotaxis, Inc. to Report Q1, 2022 Results on May 10, 2022

Stereotaxis, Inc., Annual General Meeting, May 19, 2022

Consensus revenue estimates fall by 14%

Stereotaxis, Inc. Provides Revenue Guidance for the Year 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Price target decreased to US$10.25

Stereotaxis, Inc. to Report Q4, 2021 Results on Mar 03, 2022

Price target increased to US$11.25

Forecast to breakeven in 2024

Price target increased to US$11.30

Third quarter 2021 earnings released: US$0.061 loss per share (vs US$0.026 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.02 loss per share (vs US$0.032 loss in 2Q 2020)

Insufficient new directors

Price target increased to US$9.25

Forecast to breakeven in 2024

Stereotaxis, Inc. Provides Revenue Guidance for the Year 2021

Stereotaxis to Establish Global Headquarters in Downtown St. Louis Globe Building

US$9.33 - That's What Analysts Think Stereotaxis, Inc. (NYSEMKT:STXS) Is Worth After These Results